STOK Key Statistics, Chart & Performance
The current stock price of STOK is 32.44 USD. In the past month the price increased by 3.81%. In the past year, price increased by 197.71%.
STOK Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to STOK. When comparing the yearly performance of all stocks, STOK is one of the better performing stocks in the market, outperforming 97.71% of all stocks.
STOK Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to STOK. While STOK has a great health rating, its profitability is only average at the moment.
STOK Financial Highlights
Over the last trailing twelve months STOK reported a non-GAAP Earnings per Share(EPS) of 0.75. The EPS increased by 135.71% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 19.96% | ||
| ROA | 11.39% | ||
| ROE | 13.32% | ||
| Debt/Equity | 0 |
STOK Forecast & Estimates
16 analysts have analysed STOK and the average price target is 36.47 USD. This implies a price increase of 12.41% is expected in the next year compared to the current price of 32.44.
For the next year, analysts expect an EPS growth of 110.25% and a revenue growth 941.71% for STOK
STOK Ownership
STOK Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.34 | 398.827B | ||
| AMGN | AMGEN INC | 15.51 | 182.324B | ||
| GILD | GILEAD SCIENCES INC | 16.09 | 177.765B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.18 | 118.135B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.53 | 79.79B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 48.69 | 46.476B | ||
| INSM | INSMED INC | N/A | 33.518B | ||
| NTRA | NATERA INC | N/A | 31.422B | ||
| BIIB | BIOGEN INC | 11.6 | 25.931B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.32 | 20.594B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About STOK
Company Profile
Stoke Therapeutics, Inc. is a biotechnology company, which engages in the research and development of treatments for genetic diseases. The company is headquartered in Bedford, Massachusetts and currently employs 128 full-time employees. The company went IPO on 2019-06-19. The Company, through its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach, is engaged in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its first compound, zorevunersen (STK-002), is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. TANGO aims to restore missing proteins by increasing or stoking protein output from healthy genes, thus compensating for the non-functioning copy of the gene. The firm is pursuing the development of STK-002 for the treatment of autosomal dominant optic atrophy (ADOA), the most common inherited optic nerve disorder. The Company’s initial focus is haploinsufficiency and diseases of the central nervous system and the eye.
Company Info
STOKE THERAPEUTICS INC
45 Wiggins Avenue
Bedford MASSACHUSETTS 01730 US
CEO: Edward M. Kaye
Employees: 128
Phone: 17814308200
STOKE THERAPEUTICS INC / STOK FAQ
What does STOK do?
Stoke Therapeutics, Inc. is a biotechnology company, which engages in the research and development of treatments for genetic diseases. The company is headquartered in Bedford, Massachusetts and currently employs 128 full-time employees. The company went IPO on 2019-06-19. The Company, through its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach, is engaged in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its first compound, zorevunersen (STK-002), is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. TANGO aims to restore missing proteins by increasing or stoking protein output from healthy genes, thus compensating for the non-functioning copy of the gene. The firm is pursuing the development of STK-002 for the treatment of autosomal dominant optic atrophy (ADOA), the most common inherited optic nerve disorder. The Company’s initial focus is haploinsufficiency and diseases of the central nervous system and the eye.
Can you provide the latest stock price for STOKE THERAPEUTICS INC?
The current stock price of STOK is 32.44 USD. The price decreased by -4% in the last trading session.
What is the dividend status of STOKE THERAPEUTICS INC?
STOK does not pay a dividend.
What is the ChartMill rating of STOKE THERAPEUTICS INC stock?
STOK has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
What is the GICS sector and industry of STOK stock?
STOKE THERAPEUTICS INC (STOK) operates in the Health Care sector and the Biotechnology industry.
When does STOKE THERAPEUTICS INC (STOK) report earnings?
STOKE THERAPEUTICS INC (STOK) will report earnings on 2026-03-16, after the market close.
Can you provide the short interest for STOK stock?
The outstanding short interest for STOKE THERAPEUTICS INC (STOK) is 21.6% of its float.